Nexus Pharmaceuticals, Inc. v. Exela Pharma Sciences, LLC ( 2024 )

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE NEXUS PHARMACEUTICALS, INC., Plaintiff, C.A. No. 22-1233-GBW Vv. EXELA PHARMA SCIENCES, LLC, Defendant. Kelly E. Farnan, Christine D. Haynes, RICHARDS, LAYTON & FINGER, P.A., Wilmington, DE; Imron T. Aly, Kevin M. Nelson, Adam J. Diederich, Matthew T. Wilkerson, Julie A. Vernon, ARENTFOX SCHIFF LLP, Chicago, IL Counsel for Plaintiff Robert M. Oakes, Douglas E. McCann, FISH & RICHARDSON P.C, Wilmington, DE; Corrin N. Drakulich, Christina D. Brown-Marshall, Dexter S. Whitley, FISH & RICHARDSON P.C., Atlanta, GA; Deanna J. Reichel, Sarah E. Jack, FISH & RICHARDSON P.C., Minneapolis, MN Counsel for Defendant MEMORANDUM OPINION May 6, 2024 Wilmington, Delaware Woy. Bena U.S. DISTRICT JUDGE Before the Court is the parties’ joint request that the Court construe a single term found in the claims of U.S. Patent No. 11,426,369 (the “’369 patent”). The Court has reviewed the parties’ briefing, D.I. 78, concludes that oral argument is not necessary, and construes the term at issue as set forth below. I. LEGAL STANDARDS “